1. Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation
   Milad Ashrafizadeh et al, 2024, Cancer and Metastasis Reviews CrossRef
2. A Pegylated Liposome Loaded with Raddeanin A for Prostate Cancer Therapy
   Kang He et al, 2023, International Journal of Nanomedicine CrossRef
3. TGFA expression is associated with poor prognosis and promotes the development of cervical cancer
   Xiaoxuan Ma et al, 2024, Journal of Cellular and Molecular Medicine CrossRef
4. Voluntarily wheel running inhibits the growth of CRPC xenograft by inhibiting HMGB1 in mice
   Zhaoyun Yang et al, 2023, Experimental Gerontology CrossRef
5. Elevated HMGB1 promotes the malignant progression and contributes to cisplatin resistance of non-small cell lung cancer
   Ying Ma et al, 2023, Hereditas CrossRef
6. The Effect of HMGB1 and HMGB2 on Transcriptional Regulation Differs in Neuroendocrine and Adenocarcinoma Models of Prostate Cancer
   Martín Salamini-Montemurri et al, 2024, International Journal of Molecular Sciences CrossRef
7. MCM10: An effective treatment target and a prognostic biomarker in patients with uterine corpus endometrial carcinoma
   Junyu Chen et al, 2023, Journal of Cellular and Molecular Medicine CrossRef
8. KNL1 is a prognostic and diagnostic biomarker related to immune infiltration in patients with uterine corpus endometrial carcinoma
   Kang He et al, 2023, Frontiers in Oncology CrossRef
9. CD72, a new immune checkpoint molecule, is a novel prognostic biomarker for kidney renal clear cell carcinoma
   Lv Tian et al, 2023, European Journal of Medical Research CrossRef
10. SWI/SNF chromatin remodelers in prostate cancer progression
    Sandra C. Ordonez-Rubiano et al, 2024, Frontiers in Epigenetics and Epigenomics CrossRef
11. Dipeptidase‑2 is a prognostic marker in lung adenocarcinoma that is correlated with its sensitivity to cisplatin
    Yuanyi Wang et al, 2023, Oncology Reports CrossRef